Charles River Laboratories: Value Creation Continues

Summary

  • Charles River Labs reported a strong end to 2018 and made a nice deal.
  • I like what management is doing, yet note that investors act with a bit too much enthusiasm in recent weeks.
  • While the positioning is very strong, I recognise that multiples have risen a bit while leverage is up a great deal as well, making me cautious here.
  • Looking for a community to discuss ideas with? Value In Corporate Events features a chat room of like-minded investors sharing investing ideas and strategies. Start your free trial today ยป

Charles River Laboratories (CRL) made a nice deal for Citoxlab and simultaneously reports solid 2018 results, as these new facts are welcomed by investors. I like what the company is doing, yet with shares up a third in the time frame of just a few weeks, it is time for caution here, as I am pegging a nice entry level at $115 per share.

Adding Lab, Citoxlab

Charles River has reached a deal to acquire Citoxlab for EUR 448 million in cash, equivalent to $510 million in dollar terms. With the purchase of Citoxlab, Charles River adds a non-regulated clinical research company which is focused on resulted safety assessments services, discovery services and medical device testing.

The company is active both in North America and Europe and provides a boost to Charles River's expertise in early stage CRO, adding to drug discovery and development potential.

READ FULL ARTICLE HERE